# Avalyn Pharma Inc. (AVLN) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $26.81, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Avalyn Pharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -8.1%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 35.7%**. 35.7% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): -71.3%**. Earnings per share fell 71.3%.

## Financial health
- **Current ratio: 10.19** (quick 10.19). Current assets cover the next year's liabilities 10.19 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Avalyn Pharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Avalyn Pharma Inc.; the consensus is strong_buy, with an average price target of $61.80 (+131% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -33.3%** (20.5% above the low). Trading 33% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 0.05** (volatility 64%). Beta of 0.05 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AVLN · Page: https://foliofundamentals.com/stocks/avln

Not investment advice.